91亚洲免费,无码乱人伦一区二区亚洲,在线播放中文字幕一区二区三区

首頁(yè)> 產(chǎn)品列表> 納米碳材料納米碳單元結(jié)構(gòu)材料>

Lasmiditan succinate

NMR下載 COA and HPLC MSDS下載
names：
2,4,6-Trifluoro-N-(6-((1-methylpiperidine-4-yl)carbonyl)pyridin-2-yl)benzamide succinic (21)
CAS號(hào)：
439239-92-6
MDL Number：
MF(分子式)： C42H42F6N6O8 MW(分子量)： 872.8224
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫(kù)存描述	數(shù)量	總計(jì) (￥)

大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
收藏商品商品點(diǎn)評(píng) 加入購(gòu)物車立即購(gòu)買(mǎi)

快速詢價(jià)

收起

你想詢價(jià)的產(chǎn)品

*產(chǎn)品名稱：

CAS號(hào)：

產(chǎn)品編號(hào)：

需求描述：

請(qǐng)準(zhǔn)確填寫(xiě)您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價(jià)

中文別名	Lasmiditan succinate
英文別名	COL-144; COL144; COL 144; LY573144; LY-573144; LY 573144; Lasmiditan; Lasmiditan hemisuccinate, Lasmiditan succinate;
CAS號(hào)	439239-92-6
Inchi	InChI=1S/2C19H18F3N3O2.C4H6O4/c21-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22;5-3(6)1-2-4(7)8/h22-4,9-11H,5-8H2,1H3,(H,23,24,27);1-2H2,(H,5,6)(H,7,8)
InchiKey	MSOIHUHNGPOCTH-UHFFFAOYSA-N
分子式 Formula	C42H42F6N6O8
分子量 Molecular Weight	872.8224
溶解度Solubility
性狀	Solid powder
儲(chǔ)藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說(shuō)明	Lasmiditan succinate(CAS:439239-92-6 ):僅限應(yīng)用于工業(yè)或者科學(xué)研究過(guò)程中非醫(yī)療目的，不應(yīng)用于人類或動(dòng)物的臨床診斷以及治過(guò)程療，該產(chǎn)品非藥用，非食用。
Introduction	Lasmiditan, also known as COL-144 and LY573144, is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (K1=2.21 μM) without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. Lasmiditan showed efficacy in its primary endpoint, with a 2-hour placebo-subtracted headache response of 28.8%, though with frequent reports of dizziness, paresthesias, and vertigo.
Application1
Application2
Application3

警示圖
危險(xiǎn)性	Warning
危險(xiǎn)性警示
安全聲明
安全防護(hù)
備注

[1]Curto M, Cipolla F, Cisale GY, Capi M, Spuntarelli V, Guglielmetti M, Martelletti P, Lionetto L. Profiling lasmiditan as a treatment option for migraine. Expert Opin Pharmacother. 2019 Nov 2

5:1-7. doi: 10.1080/14656566.2019.1694004. [Epub ahead of print] PubMed PMID: 31766908.

[3]Lamb YN. Lasmiditan: First Approval. Drugs. 2019 Dec;79(18):1989-1996. doi: 10.1007/s40265-019-01225-7. Review. PubMed PMID: 31749059.

[4]Wilbraham D, Berg PH, Tsai M, Liffick E, Loo LS, Doty EG, Sellers E. Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study. J Clin Pharmacol. 2019 Nov 20. doi: 10.1002/jcph.1543. [Epub ahead of print] PubMed PMID: 31745991.

[5] Knievel K, Buchanan AS, Lombard L, Baygani S, Raskin J, Krege JH, Loo LS, Komori M, Tobin J. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans. Cephalalgia. 2019 Nov 19:333102419889350. doi: 10.1177/0333102419889350. [Epub ahead of print] PubMed PMID: 31744319.

5: Ashina M, Vasudeva R, Jin L, Lombard L, Gray E, Doty EG, Yunes-Medina L, Kinchen KS, Tassorelli C. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies. Headache. 2019 Nov;59(10):1788-1801. doi: 10.1111/head.13636. Epub 2019 Sep 17. PubMed PMID: 31529622.

對(duì)不起，暫無(wú)產(chǎn)品評(píng)價(jià)！

MSDS

SDS 1.0 中文

展開(kāi)

SDS 1.0 英文

展開(kāi)